Rigel Pharmaceuticals | RIGL - Capital Ordinário





Capital Ordinário Alterar Data
Agenus USD 35.32M 2.51M 2025-12
Amgen USD 540M 1000K 2026-03
Anika Therapeutics USD 13.89M 532K 2025-12
Arrowhead Research USD 137.39M 1.69M 2025-12
AstraZeneca USD 1.55B 73K 2026-03
BioMarin Pharmaceutical USD 193.27M 969K 2026-03
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Celldex Therapeutics USD 66.57M 20K 2026-03
Daiichi Sankyo JPY 1.85B 9K 2025-12
Eli Lilly USD 943.5M 3.33M 2026-03
Halozyme Therapeutics USD 118.52M 741K 2026-03
Heron Therapeutics USD 188.31M 4.99M 2025-12
Intrexon USD 0 0 2024-06
Ionis Pharmaceuticals USD 165.9M 3.93M 2026-03
Karyopharm Therapeutics USD 18.31M 18.3M 2025-12
Ligand Pharmaceuticals USD 19.66M 19.64M 2025-09
MacroGenics USD 63.56M 241K 2026-03
Neurocrine Biosciences USD 100.6M 500K 2026-03
Pfizer USD 5.7B 13M 2026-03
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Rigel Pharmaceuticals USD 17K 158K 2024-06
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
Veracyte USD 79.79M 743K 2026-03